» Articles » PMID: 4375965

Comparative Effect and Fate of Non-entrapped and Liposome-entrapped Neuraminidase Injected into Rats

Overview
Journal Biochem J
Specialty Biochemistry
Date 1974 May 1
PMID 4375965
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Non-entrapped and liposome-entrapped Clostridium perfringens neuraminidase (0.5-0.6 unit) was injected into rats and its fate as well as its effect on plasma and erythrocyte N-acetylneuraminic acid was investigated. The following observations were made. (1) Although removal of both non-entrapped and liposome-entrapped neuraminidase from the circulation was completed within 5h after injection, their recovery in tissues was distinctly different; 7-10% of the injected non-entrapped enzyme was found in the liver and none in the liver lysosomal fraction or the spleen. In contrast, 20-26% of the liposome-entrapped enzyme was found in the liver of which 60-69% was in the lysosomal fraction. Spleen contained 3.6-5.0% of the enzyme. (2) The presence of the non-entrapped neuraminidase in blood led to the extensive desialylation of plasma and to a decrease in the concentration or total removal from the circulation of some of the plasma glycoproteins. (3) Injection of non-entrapped neuraminidase also led to the partial desialylation of erythrocytes the life span of which was diminished and their uptake by the liver and spleen augmented. (4) Entrapment of neuraminidase in liposomes before its injection prevented the enzyme from acting on its substrate in plasma or on the erythrocyte surface, and values obtained for plasma glycoproteins and erythrocyte survival were similar to those observed in control rats. (5) Entrapment in liposomes of therapeutic hydrolases intended for the degradation of substances stored within the tissue lysosomes of patients with storage diseases could prevent the potentially hazardous enzymic action of hydrolases in blood and at the same time direct the enzymes to the intracellular sites where they are needed.

Citing Articles

CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges.

Edelmann M, Maegawa G Front Mol Biosci. 2020; 7:559804.

PMID: 33304924 PMC: 7693645. DOI: 10.3389/fmolb.2020.559804.


In vivo oxalate degradation by liposome encapsulated oxalate oxidase in rat model of hyperoxaluria.

Dahiya T, Pundir C Indian J Med Res. 2013; 137(1):136-41.

PMID: 23481063 PMC: 3657877.


Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.

Thekkedath R, Koshkaryev A, Torchilin V Nanomedicine (Lond). 2012; 8(7):1055-65.

PMID: 23199221 PMC: 3644353. DOI: 10.2217/nnm.12.138.


Streptococcal neuraminidase and acute glomerulonephritis.

POTTER E, Shaughnessy M, Poon-King T, Earle D Infect Immun. 1982; 38(3):1196-202.

PMID: 7152666 PMC: 347875. DOI: 10.1128/iai.38.3.1196-1202.1982.


Adhesion and erythrophagocytosis of human senescent erythrocytes by autologous monocytes and their inhibition by beta-galactosyl derivatives.

Vaysse J, Gattegno L, Bladier D, Aminoff D Proc Natl Acad Sci U S A. 1986; 83(5):1339-43.

PMID: 3456592 PMC: 323071. DOI: 10.1073/pnas.83.5.1339.


References
1.
Gregoriadis G, Buckland R . Enzyme-containing liposomes alleviate a model for storage disease. Nature. 1973; 244(5412):170-2. DOI: 10.1038/244170a0. View

2.
Clarke H, Freeman T . Quantitative immunoelectrophoresis of human serum proteins. Clin Sci. 1968; 35(2):403-13. View

3.
Gregoriadis G, Morell A, Sternlieb I, Scheinberg I . Catabolism of desialylated ceruloplasmin in the liver. J Biol Chem. 1970; 245(21):5833-7. View

4.
Morell A, Gregoriadis G, Scheinberg I, Hickman J, ASHWELL G . The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem. 1971; 246(5):1461-7. View

5.
McQuiddy P, Lilien J . The binding of exogenously added neuraminidase to cells and tissues in culture. Biochim Biophys Acta. 1973; 291(3):774-9. DOI: 10.1016/0005-2736(73)90480-x. View